Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3b, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin in Treatment-Naïve and Treatment-Experienced Japanese Subjects With Chronic Genotype 1 HCV Infection
Brief Summary: This study will evaluate the antiviral efficacy of sofosbuvir (SOF)/ledipasvir (LDV) fixed-dose combination (FDC) tablet with or without ribavirin (RBV) in treatment-naive or treatment-experienced Japanese participants with chronic genotype 1 HCV infection. Participants receive 12 weeks of treatment and continue assessments during a 24-week posttreatment follow-up period.


Options:
A: Arm Label: SOF+RBV; Type: EXPERIMENTAL; Interventions: Drug: SOF, Drug: RBV | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to match SOF, Drug: Placebo to match RBV | Intervention Type: DRUG; Name: SOF; Assigned to Arm(s): SOF+RBV | Intervention Type: DRUG; Name: RBV; Assigned to Arm(s): SOF+RBV | Intervention Type: DRUG; Name: Placebo to match SOF; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Placebo to match RBV; Assigned to Arm(s): Placebo
B: Arm Label: Telaprevir and then Pegylated-interferon-alfa-2a+Ribavirin; Type: EXPERIMENTAL; Interventions: Drug: Telaprevir, Drug: Pegylated-interferon-alfa-2a, Drug: Ribavirin | Arm Label: Telaprevir+Pegylated-interferon-alfa-2a+Ribavirin; Type: EXPERIMENTAL; Interventions: Drug: Telaprevir, Drug: Pegylated-interferon-alfa-2a, Drug: Ribavirin | Arm Label: Placebo+Pegylated-interferon-alfa-2a+Ribavirin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pegylated-interferon-alfa-2a, Drug: Placebo, Drug: Ribavirin | Intervention Type: DRUG; Name: Telaprevir; Assigned to Arm(s): Telaprevir and then Pegylated-interferon-alfa-2a+Ribavirin, Telaprevir+Pegylated-interferon-alfa-2a+Ribavirin | Intervention Type: DRUG; Name: Pegylated-interferon-alfa-2a; Assigned to Arm(s): Placebo+Pegylated-interferon-alfa-2a+Ribavirin, Telaprevir and then Pegylated-interferon-alfa-2a+Ribavirin, Telaprevir+Pegylated-interferon-alfa-2a+Ribavirin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo+Pegylated-interferon-alfa-2a+Ribavirin | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): Placebo+Pegylated-interferon-alfa-2a+Ribavirin, Telaprevir and then Pegylated-interferon-alfa-2a+Ribavirin, Telaprevir+Pegylated-interferon-alfa-2a+Ribavirin
C: Arm Label: LDV/SOF (treatment naive); Type: EXPERIMENTAL; Interventions: Drug: LDV/SOF | Arm Label: LDV/SOF+RBV (treatment naive); Type: EXPERIMENTAL; Interventions: Drug: LDV/SOF, Drug: RBV | Arm Label: LDV/SOF (treatment experienced); Type: EXPERIMENTAL; Interventions: Drug: LDV/SOF | Arm Label: LDV/SOF+RBV (treatment experienced); Type: EXPERIMENTAL; Interventions: Drug: LDV/SOF, Drug: RBV | Intervention Type: DRUG; Name: LDV/SOF; Assigned to Arm(s): LDV/SOF (treatment experienced), LDV/SOF (treatment naive), LDV/SOF+RBV (treatment experienced), LDV/SOF+RBV (treatment naive) | Intervention Type: DRUG; Name: RBV; Assigned to Arm(s): LDV/SOF+RBV (treatment experienced), LDV/SOF+RBV (treatment naive)
D: Arm Label: PegIFN/RBV; Type: ACTIVE_COMPARATOR; Interventions: Drug: PegIFN/RBV | Arm Label: BI 201335 for 12 or 24 weeks; Type: EXPERIMENTAL; Interventions: Drug: PegIFN/RBV, Drug: BI 201335 | Arm Label: Placebo and PegIFN/RBV; Type: ACTIVE_COMPARATOR; Interventions: Drug: PegIFN/RBV, Drug: Placebo | Intervention Type: DRUG; Name: PegIFN/RBV; Assigned to Arm(s): BI 201335 for 12 or 24 weeks, PegIFN/RBV, Placebo and PegIFN/RBV | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): BI 201335 for 12 or 24 weeks | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): BI 201335 for 12 or 24 weeks | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo and PegIFN/RBV

Answer: C